New hope for HER2-mutant lung cancer: targeted drug takes on standard chemo
NCT ID NCT07178795
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This study compares a new drug, BL-M07D1, to standard chemotherapy for people with advanced or spreading non-squamous non-small cell lung cancer that has a specific HER2 gene mutation. About 440 adults will be randomly assigned to receive either the new drug or standard treatment. The main goal is to see if BL-M07D1 can delay cancer growth better than current therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact
Conditions
Explore the condition pages connected to this study.